402 related articles for article (PubMed ID: 31177425)
1. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
2. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
3. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
5. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
6. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
9. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
Strickland MR; Gill CM; Nayyar N; D'Andrea MR; Thiede C; Juratli TA; Schackert G; Borger DR; Santagata S; Frosch MP; Cahill DP; Brastianos PK; Barker FG
J Neurosurg; 2017 Aug; 127(2):438-444. PubMed ID: 27885953
[TBL] [Abstract][Full Text] [Related]
11. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
12. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and molecular characteristics of pediatric meningiomas.
Battu S; Kumar A; Pathak P; Purkait S; Dhawan L; Sharma MC; Suri A; Singh M; Sarkar C; Suri V
Neuropathology; 2018 Feb; 38(1):22-33. PubMed ID: 28901666
[TBL] [Abstract][Full Text] [Related]
14. KLF4
von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
[TBL] [Abstract][Full Text] [Related]
15. Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges.
Okano A; Miyawaki S; Hongo H; Dofuku S; Teranishi Y; Mitsui J; Tanaka M; Shin M; Nakatomi H; Saito N
Sci Rep; 2021 Mar; 11(1):6987. PubMed ID: 33772057
[TBL] [Abstract][Full Text] [Related]
16. Genomic analysis of non-neurofibromatosis type 2 meningiomas.
Parry PV; Engh JA
Neurosurgery; 2013 Jun; 72(6):N18-9. PubMed ID: 23685513
[No Abstract] [Full Text] [Related]
17. AKT1
John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
[TBL] [Abstract][Full Text] [Related]
18. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
19. Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas.
Dogan H; Blume C; Patel A; Jungwirth G; Sogerer L; Ratliff M; Ketter R; Herold-Mende C; Jones DTW; Wick W; Vollmuth P; Zweckberger K; Reuss D; von Deimling A; Sahm F
Acta Neuropathol; 2022 Oct; 144(4):799-802. PubMed ID: 35984495
[No Abstract] [Full Text] [Related]
20. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
